Provided by Tiger Trade Technology Pte. Ltd.

AN2 Therapeutics, Inc.

5.68
-0.1350-2.32%
Volume:100.95K
Turnover:581.73K
Market Cap:214.15M
PE:-5.46
High:5.82
Open:5.82
Low:5.61
Close:5.81
52wk High:7.19
52wk Low:1.00
Shares:37.74M
Float Shares:21.41M
Volume Ratio:0.63
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0401
EPS(LYR):-1.1641
ROE:-50.12%
ROA:-30.80%
PB:2.82
PE(LYR):-4.88

Loading ...

AN2 Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

AN2 Therapeutics Q1 FY26 net loss narrows 5.83% to $10 million

Reuters
·
May 12

AN2 Therapeutics Q1 EPS USD -0.29

THOMSON REUTERS
·
May 12

Press Release: AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Dow Jones
·
May 12

AN2 Therapeutics CEO joins Stifel Virtual Targeted Oncology Forum fireside chat

Reuters
·
May 08

AN2 Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
Apr 30

AN2 Therapeutics announces annual shareholder meeting

Reuters
·
Apr 23

BRIEF-AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies

Reuters
·
Apr 21

AN2 Therapeutics Inc - Enters Open Market Sale Agreement With Jefferies Llc Dated April 9, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 21

AN2 Therapeutics Inc - May Offer and Sell Common Stock up to $80 Mln Through Jefferies - SEC Filing

THOMSON REUTERS
·
Apr 21

BRIEF-An2 Therapeutics Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing

Reuters
·
Apr 10

AN2 Therapeutics Files $300 Million Mixed Shelf

MT Newswires Live
·
Apr 10

AN2 Therapeutics files $300M mixed securities shelf

TIPRANKS
·
Apr 10

AN2 Therapeutics Inc - May Offer up to $80 Mln of Common Stock Under Agreement With Jefferies Llc - SEC Filing

THOMSON REUTERS
·
Apr 10

AN2 Therapeutics Inc - Enters Open Market Sale Agreement With Jefferies for up to $80 Mln Common Stock - SEC Filing

THOMSON REUTERS
·
Apr 10

AN2 Therapeutics Inc - Terminates TD Cowen Sales Agreement Effective April 9, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 10

AN2 Therapeutics enters $80 million at-the-market equity sales agreement with Jefferies

Reuters
·
Apr 10

AN2 Therapeutics starts Phase 2 epetraborole trial in M. abscessus lung disease

Reuters
·
Apr 01

AN2 Therapeutics Inc - Expects Three Phase 2 Studies Active in 2026

THOMSON REUTERS
·
Mar 31

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium Abscessus Complex Lung Disease

THOMSON REUTERS
·
Mar 31